Repligen reported 12.5% year-on-year organic revenue growth and adjusted EBITDA margin expansion of 1.9 percentage points. Management now expects full-year adjusted EBITDA margin of 21%, at the top of its previous guidance range of 20.6%-21.0%.
Repligen offers investors exposure to the rapidly growing and moatworthy bioprocessing industry and its market-leading product offerings.
Repligen’s adjusted EBITDA margins are around 20%, lagging the industry average of the high 20s.
|
Metric
|
RGEN
|
TMO
|
SRT3
|
|---|---|---|---|
Price/Earnings (Normalized) | 89.24 | 31.15 | 81.61 |
Price/Book Value | 4.76 | 4.68 | 6.84 |
Price/Sales | 12.33 | 5.47 | 5.49 |
Price/Cash Flow | 52.51 | 24.85 | 27.05 |
|
Metric
|
RGEN
|
TMO
|
SRT3
|
|---|---|---|---|
Quick Ratio | 7.30 | 1.01 | 0.43 |
Current Ratio | 9.05 | 1.55 | 1.07 |
Interest Coverage | 3.35 | 5.57 | 4.03 |
|
Metric
|
RGEN
|
TMO
|
SRT3
|
|---|---|---|---|
Return on Assets (Normalized) | 3.80% | — | 3.58% |
Return on Equity (Normalized) | 5.32% | — | 12.52% |
Return on Invested Capital (Normalized) | 4.64% | — | 5.41% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Intuitive Surgical Inc
ISRG
| LOCK|%#^#f!yt | LOCK|%!P | $158B | |||
| Becton Dickinson & Co
BDX
| LOCK|bby | LOCK|#@!Ck | $53B | |||
| ResMed Inc
RMD
| LOCK|?YWgWB# | LOCK|%Vp?V | $35B | |||
| Alcon Inc
ALC
| LOCK|%Tnxlgc | LOCK|%W%sm | $34B | |||
| Medline Inc Ordinary Shares - Class A
MDLN
| LOCK|$@$#<V# | LOCK|QVZ^ | $28B | |||
| West Pharmaceutical Services Inc
WST
| LOCK|C&%fQg< | LOCK|sX^ | $28B | |||
| Solventum Corp
SOLV
| LOCK|kjkPByp | LOCK|bT | $14B | |||
| Baxter International Inc
BAX
| LOCK|$k | LOCK|?$<N | $13B | |||
| The Cooper Companies Inc
COO
| LOCK|$bRCy< | LOCK|V?$dM | $11B |
United States